Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus +/- Exemestane vs Capecitabine in Advanced Breast Cancer
NCT01783444Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2013
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 2, randomised, open-label trial of everolimus in breast cancer (3 arms), sponsored by Novartis. Primary endpoint: Progression Free Survival up to 39 months. Started Feb 2013; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01783444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01783444.